Clene (CLNN) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
10 Apr, 2026Executive summary
The annual meeting is scheduled for May 21, 2026, with voting available online, by phone, mail, or in person, and only shareholders of record as of March 25, 2026, are eligible to vote.
Four main proposals are up for vote: election of three Class III directors, ratification of Deloitte as auditor, advisory approval of executive compensation, and an amendment to increase shares in the 2020 Stock Plan.
The board recommends voting in favor of all proposals and provides detailed instructions for proxy voting and revocation.
Voting matters and shareholder proposals
Shareholders will vote on electing three Class III directors for terms ending in 2029, ratifying Deloitte as auditor for 2026, approving executive compensation on an advisory basis, and amending the 2020 Stock Plan to add 1,000,000 shares.
The board recommends voting “FOR” all proposals; directors are elected by plurality, while other proposals require a majority of votes cast.
Shareholder proposals and director nominations for the 2027 meeting must be submitted between January 21 and February 20, 2027.
Board of directors and corporate governance
The board consists of nine directors divided into three classes with staggered three-year terms; a majority are independent.
Committees include Audit, Compensation, and Nominating and Corporate Governance, all composed of independent directors.
The board emphasizes diversity, ethical conduct, and strong governance, with a code of conduct and policies for conflicts of interest.
Directors are encouraged to attend all meetings and participate in continuing education.
Latest events from Clene
- Net loss widened to $13.4M in Q2 2026, with ongoing funding concerns and rising R&D costs.CLNN
Q2 2026 - NDA filing for a novel ALS therapy is planned for early Q4, supported by new biomarker data.CLNN
Canaccord Genuity's 46th Annual Growth Conference - FDA meeting and NDA filing for ALS therapy targeted in 2024, with strong survival data presented.CLNN
Emerging Growth Virtual Conference - FDA supports NDA submission for ALS drug based on neurofilament reduction; MS phase III planned.CLNN
Emerging Growth Conference 92 - Net loss was $8.1M in Q1 2026; NDA for CNM-Au8 in ALS planned for Q3 2026.CLNN
Q1 2026 - Key votes include director elections, auditor ratification, and stock plan share increase.CLNN
Proxy filing - Net loss narrowed in 2025, with strong financing and positive ALS biomarker data supporting NDA plans.CLNN
Q4 2025 - CNM-Au8 significantly reduced ALS biomarkers and improved survival, supporting accelerated approval.CLNN
Study Update - Significant clinical progress and regulatory milestones expected for nanotherapeutics in ALS and MS.CLNN
Q2 Virtual Investor Summit Event